Literature DB >> 20682714

HER2 fragmentation and breast cancer stratification.

Joaquín Arribas1, Josep Lluís Parra-Palau, Kim Pedersen.   

Abstract

HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as p95HER2. These fragments are emerging as a valuable biomarker for this subset of patients, who have a particularly poor prognosis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20682714     DOI： 10.1158/1078-0432.CCR-10-1501

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.

Authors:  Karim Salazar-Salinas; Carlos Kubli-Garfias; Jorge M Seminario
Journal:  J Mol Model       Date:  2012-11-10       Impact factor: 1.810

2.  Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.

Authors:  Dhong Hyo Kho; Pratima Nangia-Makker; Vitaly Balan; Victor Hogan; Larry Tait; Yi Wang; Avraham Raz
Journal:  Cancer Res       Date:  2012-12-17       Impact factor: 12.701

3.  Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.

Authors:  T M Ward; E Iorns; X Liu; N Hoe; P Kim; S Singh; S Dean; A-M Jegg; M Gallas; C Rodriguez; M Lippman; R Landgraf; M D Pegram
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

4.  Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform.

Authors:  Esmaeil Dorraji; Elin Borgen; Dario Segura-Peña; Puneet Rawat; Eva Smorodina; Claire Dunn; Victor Greiff; Nikolina Sekulić; Hege Russnes; Jon Amund Kyte
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

5.  Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Authors:  Galatea Kallergi; Sofia Agelaki; Maria A Papadaki; Dimitris Nasias; Alexios Matikas; Dimitris Mavroudis; Vassilis Georgoulias
Journal:  Breast Cancer Res       Date:  2015-08-19       Impact factor: 6.466
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.